Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 18/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | ULK1 | O75385 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752965 | 0.87 | ALK (1.00) | ALKEGFRULK1 | |
| SCHEMBL4562782 | 0.87 | ALK (0.72) | ALKEGFR | |
| SCHEMBL16752944 | 0.81 | ALK (1.00) | ALK | |
| SCHEMBL16752967 | 0.81 | ALK (1.00) | ALK | |
| SCHEMBL29832366 | 0.79 | EGFR (1.00) | ALKEGFR | |
| SCHEMBL21846968 | 0.79 | EGFR (1.00) | ALKEGFR | |
| SCHEMBL17530379 | 0.79 | ALK (0.82) | ALKEGFRULK1 | |
| SCHEMBL13895953 | 0.77 | ALK (0.70) | ALKEGFRULK1 | |
| SCHEMBL1613786 | 0.77 | ALK (0.70) | ALKEGFRULK1 | |
| SCHEMBL26612049 | 0.77 | ALK (0.75) | ALKEGFRULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306067-A1 | 2, 4-DIAMINOPYRIMIDIDE DERIVATES AND THEIR USE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306067-A1 | 2, 4-DIAMINOPYRIMIDIDE DERIVATES AND THEIR USE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306067-A1 | 2, 4-DIAMINOPYRIMIDIDE DERIVATES AND THEIR USE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2007115999-A1 | 2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306067-A1 | 2, 4-DIAMINOPYRIMIDIDE DERIVATES AND THEIR USE FOR THE TREATMENT OF CANCER | MKI67, CCND1, CCNT1 | ALK 455/4885EGFR 75/4885ULK1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.